Venus Remedies Earns Prestigious REO Certification from CII for Second Consecutive Year

▴ Venus Remedies Limited
As the first pharmaceutical company in India to be honored with the REO certification from CII, Venus Remedies stands at the forefront of responsible and sustainable export practices. The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian Industry (CII).

Chandigarh, October 20, 2023: Venus Remedies is thrilled to announce that it has once again achieved the highly coveted Responsible Export Organisation (REO) certification from the Confederation of Indian Industry (CII). This achievement marks the second consecutive year that Venus Remedies has been recognized with this prestigious certification, reinforcing the company's unwavering commitment to excellence in the pharmaceutical industry.

 

As the first pharmaceutical company in India to be honored with the REO certification from CII, Venus Remedies stands at the forefront of responsible and sustainable export practices. This recognition comes after a rigorous and comprehensive screening and assessment process, emphasizing the company's dedication to upholding the highest standards of quality and integrity.

 

The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian Industry (CII) to companies that demonstrate exceptional commitment to responsible and sustainable export practices, ensuring high standards of quality, ethics, and integrity in their international business operations.

 

Mr. Peeyush Jain, Deputy Managing Director at Venus Remedies, expressed his gratitude for this remarkable achievement, stating, "The REO certification from the CII will enable us to expand our presence in our targeted 100 countries. The certification confirms our commitment to enhancing the lives of our members, improving workplaces, and contributing to a better world through the application of quality tools, techniques, and systems. It also serves as an endorsement of our company's export capabilities and manufacturing processes."

 

The REO certification underscores Venus Remedies' dedication to responsible and ethical business practices, setting the company apart as a leader in the global pharmaceutical landscape. It reflects the rigorous evaluation and recognition of the organization's systems and procedures as exemplary within the industry.

 

"This certification will empower our company to continue its upward trajectory and solidify its position as an export industry leader," continued Mr. Peeyush Jain. "The CII team has assessed our systems and procedures and found them to be exemplary within the organization. This certification will further assist us in enhancing our performance and setting standards of excellence."

 

Venus Remedies remains committed to maintaining the highest standards in pharmaceutical manufacturing, quality control, and ethical exporting practices. “We are immensely proud of this accomplishment, and it is an outcome of our team's dedication and hard work. Achieving the REO certification for the second consecutive year highlights our resolute to make a positive impact in the pharmaceutical industry. We remain steadfast in our pursuit of excellence, driving innovation, and delivering high-quality healthcare solutions to communities worldwide,” Akshansh Chaudhary, Executive Director & Chief Technology Officer, Venus Remedies.

 

About Venus Remedies

Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 70+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. Its manufacturing units are certified for ISO 9001, ISO 14001, ISO 18001 and OHSAS. The company has also been approved by European- GMP, WHO-GMP and Latin American GMP (INVIMA), among others. Ranked 107th in Asia and among the world’s 500 largest pharmaceutical manufacturing companies, Venus Remedies has been granted more than 130 patents worldwide and having more than 125 registered trademarks and 25 copyrights for its innovative research products.

Tags : #venusremedies #REO #certification #CII #pharmaceutical #pharma #healthcare #medicircle

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Achieving Healthier Lifestyles: Understanding India's New Dietary GuidelinesMay 11, 2024
The Link Between Childhood Sleep and Adult Psychosis: A Critical AnalysisMay 11, 2024
Uncovering Immunization Gaps: Insights into Measles Vaccination Challenges in IndiaMay 11, 2024
Unlocking New Horizons: Gene Therapies for Hearing Loss and BlindnessMay 10, 2024
Kerala Health Alert: West Nile Fever Cases Confirmed in Thrissur, Malappuram, and KozhikodeMay 10, 2024
Managing Health in the Heat: Demand for Medications Surges in IndiaMay 10, 2024
Sudhamukti Ayurvedic Medicine by OJSP: A New Era in Diabetes ManagementMay 10, 2024
The Role of Genetic Profiles in Alzheimer’s Therapy: APOE4 and Treatment ResponsesMay 08, 2024
Assessing Covishield Safety: Indian Research Offers Reassurance Amidst Rare Side Effect DiscussionsMay 08, 2024
Quadria Capital Invests $102 Million in NephroPlus to Boost Dialysis Services Across AsiaMay 08, 2024
Reducing Stigma, One Story at a Time: Media's Role in Mental HealthMay 07, 2024
When Your Body Makes Beer: Exploring the Curious Case of Auto-Brewery SyndromeMay 07, 2024
Hair Today, Gone Tomorrow: Why Guys Go Bald Before Marriage May 07, 2024
Menopausal Transitions and Mental Health: UCL Study Highlights Increased Depression RiskMay 07, 2024
Vasavi Club of Buddhapurnima organised #GoVote, a vote awareness driveMay 06, 2024
Vasavi Club of Buddhapurnima organised #GoVote, a vote awareness driveMay 06, 2024
Harnessing AI for Early Alzheimer's Disease Diagnosis: IIT Indore's BreakthroughMay 06, 2024
Aurobindo Pharma's Bhiwadi Facility Under FDA Scrutiny: Understanding the ObservationsMay 06, 2024
Exploring the Role of Mediator Protein Complex in Cell Division: Implications for Disease ManagementMay 06, 2024
Akshay Tritiya Parna Mahotsav is to be held in the cityMay 04, 2024